The effect of vitamin D3 on CD34 progenitor cells in vitamin D deficiency rickets

Sevgi Yetgin¹, S. Songül Yalçın²

Units of ¹Pediatric Hematology, and ²Social Pediatrics, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey


Vitamin D metabolites have multiple functions not only in calcium homeostasis, but also in hematopoiesis. To detect the effect of vitamin D on hematopoiesis with a surface glycoprotein marker, the proportions of the CD34+ cells were measured in bone marrow, peripheral blood and spleen prior to and after vitamin D3 treatment in an infant with severe rickets, myelofibrosis and myeloid metaplasia. CD34+ cells measured 0.4% in bone marrow, 8.0% in peripheral blood and 8.7% in splenic aspirate. The detection of a high and comparable level of CD34+ cells in both peripheral blood and splenic aspirate on admission and the decline in the level of CD34+ cells (2%) following treatment support that CD34+ cells were from extramedullary hematopoiesis in spleen. The improvement of rickets and hematological findings with treatment at the same time raises the possibility of vitamin D3 acting directly upon the same target or upon different targets at the same time or of the presence of interaction between two targets. Our findings may also show a relation between vitamin D3 and its metabolites to bone marrow stem cells.

Key words: rickets, CD34 cells, infant, hematopoiesis, vitamin D.

Traditionally perceived as a secosteroid hormone involved in calcium homeostasis, vitamin D metabolites might have roles in immunoregulation and hematopoietic differentiation1. The effect on bone remodeling and the hematopoietic system was examined in cases with vitamin D deficient rickets2,3. It was shown that 1,25 (OH)₂D₃ inhibited the proliferation of colonogenic blast cells and induced acute myeloblastic leukemia (AML) cell lines to differentiate into macrophage-like cells in vitro4-6. In contrast, normal human granulocyte-monocyte committed stem cells are slightly stimulated into their clonal proliferation by 1,25 (OH)₂D₃7.

The CD34 is a surface glycoprophosphoprotein expressed on committed and primitive hematopoietic stem cells8. In normal individuals, CD34+ cells comprise approximately 1 to 5% of bone marrow cells and 0.1% of peripheral blood cells8. CD34+ cells can thus be examined to detect the changes in hematopoietic stem cells. In a previous study, it was shown that the proportion of D34+ cells in peripheral blood did not change in rachitic patients without myeloid metaplasia9.

Grande et al.10 reported that physiological levels of vitamin D promote a differentiation of CD34+ hematopoietic progenitors characterized by the induction of all the monomacrophagic immunophenotypic and morphological markers in a liquid culture model; however, there was no study about changes in the CD34 cells in rachitic patients with myelofibrosis.

Previously, we reported hematopoietic suppression in children with vitamin D deficient rickets and the improvement of the hematologic findings with administration of vitamin D2,3. In an infant with rickets, myelofibrosis and myeloid metaplasia, we examined the proportion of the CD34+ cells in bone marrow, peripheral blood and spleen prior to and after vitamin D treatment, to clarify the effect of vitamin D on hematopoiesis with a surface glycoprotein marker, the CD34, in vivo.

Case Report

A five-month-old was referred to Hacettepe Children’s Hospital because of diarrhea, anemia and hepatosplenomegaly. His weight was 5000 g (<5th percentile), length 59 cm (<5th
percentile) and head circumference 38.5 cm (<5th percentile). Physical examination revealed pallor, metaphyseal enlargement of wrists, rachitic rosaries, craniotabes, hepatomegaly (5 cm below the right costal margin) and splenomegaly (6 cm below the left costal margin). Laboratory data were as follows: hemoglobin 6.7 g/dl, hemotocrit 23%, reticulocyte 3%, leukocytes 4.7×10⁹/L (41% neutrophils, 3% bands, 5% myelocytes, 2% metamyelocytes, 11% normoblasts, 9% monocytes, 29% lymphocytes), and platelet count 62×10⁹/L, erythrocyte anisopoikilocytosis was noted in the blood smear. Serum calcium was 8 mg/dl, phosphorus 1.5 mg/dl, alkaline phosphatase 437 U/L, total protein 6.4 g/dl, and albumin 3.9 g/dl. Liver and renal function tests were normal. The X-ray findings of wrist were typical for rickets. When examined for hemolytic anemia, results of direct and indirect Coombs’ test and cold agglutinins were negative. Fetal hemoglobin was 5%, appropriate for his age. The results of parental hemoglobin electrophoresis were normal. Sickling test was negative. Serum iron level was 120 µg/dl and serum iron binding capacity 250 µg/dl. The levels of serum immunoglobulins were normal. Serologic tests for rubella and toxoplasma were negative.

Bone marrow aspirations which were done three times yielded no bone marrow specimen. Bone marrow was obtained by bone marrow biopsy and myelofibrosis was detected. Splenic aspirates revealed myeloid metaplasia. The CD34 counts were 8.0% in peripheral blood, 0.4% in bone marrow and 8.7% in splenic aspirate. The child was treated with a single oral dose of vitamin D (600,000 IU). Three months after treatment, the patient’s liver and spleen returned to normal size. Hemoglobin level was 11.0 g/dl, leukocyte count 6.3×10⁹/L, platelet count 149×10⁹/L, and CD34 counts 2%. The infant’s previously described morphological abnormalities in peripheral blood smear had resolved.

**Discussion**

In this case the diagnosis of rickets due to vitamin D deficiency was based on a history of inadequate vitamin D intake and clinical findings and absence of any other disease causing these hematological findings and was proven by serum assay, X-ray and prompt reversal after vitamin D treatment. In our clinic, in cases with vitamin D deficiency rickets, hepatosplenomegaly, anemia, thrombocytopenia, myeloid metaplasia and myelofibrosis have previously been reported. All the clinical and hematological findings, including findings of rickets improved, following vitamin D treatment in our patients²³. In this case it was thought that myelofibrosis in bone marrow caused hematopoietic suppression and enlargement of spleen as a result of extramedullary hematopoiesis. As CD34⁺ cells decreased in bone marrow, the detection of a high and comparable level of CD34⁺ cells in both peripheral blood and splenic aspirate strongly suggested that CD34⁺ cells originated from the spleen. The decline in the level of CD34⁺ cells (from 8% to 2%) following treatment supports that the origin of CD34⁺ cells was extramedullary hematopoiesis in the spleen in this patient with severe rickets and myelofibrosis. It was reported that vitamin D has differentiation on multi-lineage or myeloid precursor cells instead of the increase in hematopoietic cells⁴⁻⁶. Furthermore, vitamin D3 has been shown to be a very potent inhibitor of CD34⁺ leukemic blasts while preserving clongenic activity of normal human CD34⁺ hematopoietic progenitor cells⁴⁻⁶. In our rachitic case with myelofibrosis, the level of CD34⁺ cells in bone marrow was decreased. This data shows the proliferation effect of vitamin D on bone marrow stem cells in addition to the differentiation effect. However, this can be valid for CD34⁺ cells. In addition, the improvement of rickets and hematological findings with treatment at the same time raises the possibility of vitamin D acting directly upon the same targets or upon different targets at the same time or of the presence of interaction between two targets.
cytokines\textsuperscript{11-13}. However, due to a lack of osteoblast specific cell-surface markers, the link between hematopoiesis and osteoblasts has not been easy to define. Recently, Visnjic et al.\textsuperscript{14} reported that hematopoietic cell development in the bone marrow was arrested in mice with an induced osteoblast deficiency. In addition, the conversion of HL-60 cells to multinuclear giant cells and to cells involved in bone matrix degradation supports that the osteoclasts are also from hematopoietic stem cell origin and are thought to be derived from immature marrow cells of monocyte/macrophage lineage\textsuperscript{5,15}. Thus, in view of the evidence, it is likely that bone tissue and hematopoietic cells might be from the same cell origin.

Morphologic and functional studies have shown that immature mouse myeloid leukemia cells and the human promyelocytic leukemia cell line (HL-60) differentiated to mature macrophage-like cells upon treatment with 1-25 (OH)\textsubscript{2} D\textsubscript{3} with the reduced proliferation of these cells\textsuperscript{4-6}. Our study is an evidence that vitamin D\textsubscript{3} treatment may have suppressed extramedullary hematopoiesis in vivo in a rachitic case with myelofibrosis, and both, differentiation and proliferation in bone marrow. It is concluded that vitamin D could exert its influence not only by stem cell differentiation but also by proliferation.

REFERENCES